Logo

ACONW

Aclarion, Inc.

ACONW

Aclarion, Inc. • NASDAQ
$0.04 ▲ 0.00% (+0.00)
Market Cap $23270
52w High $0.05
52w Low $0.04
Dividend Yield 0%
P/E -0.01
Volume 3.67K
Outstanding Shares 581.75K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $18.942K ▼ $1.835M ▲ $-1.706M ▼ -9.008K% ▼ $-2.93 ▼ $-1.648M ▼
Q2-2025 $19.319K ▲ $1.742M ▲ $-1.601M ▲ -8.286K% ▲ $-2.749 ▲ $-1.548M ▲
Q1-2025 $18.991K ▲ $1.487M ▼ $-2.037M ▼ -10.728K% ▲ $-9.318 ▲ $-1.982M ▼
Q4-2024 $10.232K ▼ $1.796M ▲ $-1.99M ▼ -19.445K% ▼ $-1.588K ▼ $-1.937M ▼
Q3-2024 $14.407K $1.289M $-1.366M -9.483K% $-1.321K $-1.245M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $11.341M ▼ $13.2M ▼ $699.747K ▲ $12.501M ▼
Q2-2025 $12.865M ▼ $14.755M ▼ $564.422K ▼ $14.19M ▼
Q1-2025 $14.75M ▲ $16.48M ▲ $699.032K ▼ $15.781M ▲
Q4-2024 $453.661K ▼ $2.123M ▼ $1.153M ▲ $970.057K ▼
Q3-2024 $1.312M $3.188M $678.267K $2.51M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.706M ▼ $-1.16M ▲ $-40.151K ▲ $-283.798K ▼ $-1.484M ▲ $-1.168M ▲
Q2-2025 $-1.601M ▲ $-1.866M ▲ $-44.002K ▲ $-1 ▼ $-1.91M ▼ $-1.866M ▲
Q1-2025 $-2.037M ▼ $-2.511M ▼ $-78.288K ▼ $16.886M ▲ $14.297M ▲ $-2.589M ▼
Q4-2024 $-1.99M ▼ $-899.487K ▲ $-60.717K ▲ $101.767K ▼ $-858.437K ▼ $-904.6K ▲
Q3-2024 $-1.366M $-1.056M $-103.697K $1.299M $139.411K $-1.159M

Five-Year Company Overview

Income Statement

Income Statement The company is essentially still pre-revenue in the reported period, with only small operating losses showing up. That means the story today is almost entirely about future potential rather than current earnings power. The wild swings you see in per‑share figures are more about changes in the share count and capital structure than about any real change in the underlying business performance. Overall, this is an early‑stage profile: minimal sales, no clear path to consistent profitability yet, and heavy dependence on proving out the technology and ramping commercial adoption over time.

Balance Sheet

Balance Sheet The reported balance sheet data are very thin and look more like a development‑stage company than an established healthcare business. Assets and cash are effectively negligible in the dataset, and equity only recently moved from slightly negative to roughly neutral, which signals limited financial cushion and a likely reliance on outside funding to keep operations going. In practical terms, this suggests a fragile capital base: future growth will probably depend on additional equity raises, partnerships, or other external capital until the product begins to generate meaningful revenue. The numbers may also be somewhat incomplete, so there is extra uncertainty here.

Cash Flow

Cash Flow Cash flow figures show small but consistently negative operating cash flow and free cash flow, which is what you would expect from a company still building out its technology and market presence. There is virtually no capital spending, which fits an asset‑light, software‑driven model, but it also means nearly all cash use is going to salaries, R&D, and commercialization efforts. The key takeaway is ongoing cash burn with no self‑funding from operations yet, so the business remains dependent on capital markets or partners to finance its plans until it can turn its technology into recurring, paying usage at scale.

Competitive Edge

Competitive Edge Aclarion operates in a very specific niche within healthcare information services: diagnostic support for chronic low back pain. Its Nociscan platform aims to replace an invasive, uncomfortable legacy procedure with a non‑invasive, software‑enhanced scan, which, if widely adopted, could be very attractive to patients, surgeons, and payors. The company’s competitive strengths lie in being a first mover with a focused solution, strong patent protection, and emerging clinical evidence. On the other hand, it is a small player in a market where large imaging, med‑tech, and spine‑surgery companies have deep relationships, big sales forces, and more resources. Adoption, reimbursement, and clinician behavior are all major uncertainties. The partnership with an established spine‑surgery company is a positive sign, but market penetration is still at a very early stage and will likely be slow and data‑driven.

Innovation and R&D

Innovation and R&D Innovation is the core of this story. Nociscan uses advanced MRI‑based spectroscopy plus cloud software and algorithms to identify which spinal discs are likely causing pain, turning a subjective, invasive test into an objective, non‑invasive one. The company has built a sizable patent portfolio around this approach, including broader rights to detect certain pain‑related biomarkers in other parts of the body, which could open up future indications. A pivotal clinical trial (CLARITY) is underway to generate top‑tier evidence on outcomes and cost‑effectiveness; its results will be critical for physician adoption and insurance coverage. In short, the R&D and IP base are meaningful strengths, but success depends on converting that science into real‑world usage, clear clinical guidelines, and payer support—each of which can take years and carries significant risk.

Summary

Overall, Aclarion looks like a highly early‑stage, research‑heavy healthcare technology company where the investment case is almost entirely about future potential rather than current financial performance. The financials show negligible revenue, ongoing losses, and continued cash burn, implying reliance on fresh capital and a modest balance‑sheet buffer. At the same time, the company has a differentiated technology aimed at a large and painful clinical problem, backed by patents and growing clinical data, plus a partnership that could help commercialization. The key watch points are: progress in the pivotal clinical trial, real‑world adoption trends and reimbursement decisions, evidence of recurring commercial revenue, and how the company manages its cash runway and dilution risk along the way.